Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

New method to repair pain

A study published in the scientific journal Nature Neuroscience by Yves De Koninck and Robert Bonin, two researchers at Universit- Laval, reveals that it is possible to relieve pain hypersensitivity using a new method that involves rekindling pain so that it can subsequently be erased.

9 Jul 2014

Researchers discover how metal beryllium triggers deadly immune response in the lungs

Using exquisitely detailed maps of molecular shapes and the electrical charges surrounding them, researchers at National Jewish Health have discovered how the metal beryllium triggers a deadly immune response in the lungs.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

Henry Ford Health System has launched a clinical trial to investigate a new drug for the treatment of tinnitus, a chronic ringing of the head or ears that affects more than 600 million people worldwide.

25 Jun 2014

OAB and interstitial cystitis/bladder pain syndrome show considerable overlap

There is considerable overlap between symptoms in patients with interstitial cystitis/bladder pain syndrome and those with overactive bladder, US researchers have shown.

23 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.

5 Jun 2014

SYNERA can help prevent needle stick pain associated with superficial IVs

Galen US Incorporated today announced that the U.S. Food and Drug Administration (FDA) recently approved a labeling change that allows SYNERA® (lidocaine and tetracaine) topical patch to be used at home.

4 Jun 2014

New antibody appears to block sensations of pain, itching in mouse model

Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice.

23 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

Innate immune response may warn of chronic multisite musculoskeletal pain

An enhanced innate immune response may be an indicator of the onset or prolongation of chronic, multisite musculoskeletal pain, cross-sectional study findings suggest.

19 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

12 May 2014

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Hypersensitivity News and Research

New method to repair pain

Researchers discover how metal beryllium triggers deadly immune response in the lungs

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Henry Ford launches clinical trial for treatment of tinnitus caused by noise trauma

OAB and interstitial cystitis/bladder pain syndrome show considerable overlap

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

SYNERA can help prevent needle stick pain associated with superficial IVs

New antibody appears to block sensations of pain, itching in mouse model

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

Innate immune response may warn of chronic multisite musculoskeletal pain

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Cumberland launches new Vaprisol product

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News